Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Breast Neoplasms

Triple Negative Breast Neoplasms

Breast Diseases

Skin Diseases

Antineoplastic Agents

All Drugs and Chemicals

Antirheumatic Agents

Paclitaxel

Docetaxel

Albumin-Bound Paclitaxel

Carboplatin

Cyclophosphamide

Doxorubicin

Liposomal doxorubicin

Taxane

Doxorubicin (60 mg/m2) IV + cyclophosphamide (600 mg/m2) IV every 3 weeks for 4 cycles followed by taxane plus carboplatin for 4 cycles The taxane plus carboplatin regimen can be selected based on the investigator's discretion from among the following two regimens.

* Docetaxel (75 mg/m2) IV plus carboplatin (AUC 5) IV every 3 weeks for 4 cycles
* Paclitaxel (80 mg/m2) IV weekly for 12 doses plus carboplatin (AUC 5) IV every 3 weeks for 4 cycles

taxane plus carboplatin

Doxorubicin (60 mg/m2) IV + cyclophosphamide (600 mg/m2) IV every 3 weeks for 4 cycles followed by taxane for 4 cycles The taxane regimen can be selected at the investigator's discretion from among the following two regimens.

* Docetaxel (75 mg/m2) IV every 3 weeks for 4 cycles
* Paclitaxel (80 mg/m2) IV weekly for 12 doses

Ki Hyeong Lee, MD, PhD

Keun Seok Lee, MD, PhD

Soo Jung Hong, Md, PhD

Yong Hwa Moon, MD, PhD

Seok Yun Kang, MD

Han Jo Kim, MD

Sung Sook Lee, Md, PhD

Keon Uk Park, MD, PhD

Eun Kyung Cho, MD, PhD

Se Hyun Kim, MD

Kyung Hae Jung, Md, PhD

Jin Hyun Park, MD

Ji Eun Lee, MD, PhD

Hee Jun Kim, MD, PhD

Hei Cheul Jeung, Md, PhD

Kyong Hwa Park, MD, PhD

Sun Kyung Baek, MD

Young Hyuck Im, MD, PhD

Joo Hyuk Sohn, MD, PhD

Su Jin Koh, MD, PhD

Seung Taek Lim, MD

This is a randomized, open-label, multicenter, phase III study comparing anthracyclines followed by taxane to anthracyclines followed by taxane plus carboplatin as (neo)adjuvant therapy in patients with triple-negative breast cancer.

Patients with stage II/III operable triple-negative breast cancer are eligible. Patients who need adjuvant chemotherapy after breast surgery as well as patients who need neoadjuvant chemotherapy for TNBC are eligible.

Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial)

A Randomized, Multicenter, Open-label, Phase III Trial Comparing Anthracyclines Followed by Taxane Versus Anthracyclines Followed by Taxane Plus Carboplatin as (Neo) Adjuvant Therapy in Patients With Triple-negative Breast Cancer

time from randomization to the occurrence of the following events

: loco-regional recurrence, distant recurrence, death from any cause, contralateral invasive breast cancer, second primary cancer, and clinically inoperable and residual disease at surgery (only in the neoadjuvant population)

Yonsei University

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial)	NCT02441933	Breast Cancer	taxane plus car... Taxane	19 Years -	Yonsei University
Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial)	NCT02441933	Breast Cancer	taxane plus car... Taxane	19 Years -	Yonsei University

Spots Global Cancer Trial Database for taxane plus carboplatin